WHO ICTRP trial
A phase I, single-centre, randomised, single-blinded, placebo-controlled single…
NL-OMON35929 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON35929 |
|---|---|
| Public title | A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers. |
| Scientific title | A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers. - ALX 0651 SAD and… |
| Primary sponsor | Ablynx NV |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | stamcel mobilisatie beenmerg bloedvormende stamcellen;beenmerg;bloedvormende stamcellen |
| Interventions | ALX-0651 as bolus injection for first dose level, rest by iv ;ALX 0651;blood forming stem cells;Bone marrow |
| Registration date | Nov 8, 2011 |
| Target size | 76 |
| Secondary IDs | 2011-001135-23;NL36986.056.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: